期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

NLRP3炎症小体与糖尿病慢性并发症的关系及中药干预作用 被引量：5

Relationship between NLRP3 Inflammasome and Chronic Complications of Diabetes and Therapeutic Effects of Chinese Herbal Medicine
下载PDF
导出
摘要 NLRP3炎症小体是模式识别受体的一种,可通过活化含半胱氨酸的天冬氨酸蛋白酶调控白细胞介素-1β、-18等炎症因子的成熟和分泌,引发炎症反应。近年研究发现,在慢性高糖状态下葡萄糖、游离脂肪酸、尿酸等代谢应激均可激活NLRP3炎症小体,成为糖尿病及慢性并发症的新靶标。本文总结了NLRP3炎症小体与糖尿病慢性并发症的关系及中药干预作用的研究进展。 NLRP3 inflammasome is a pattern recognition receptor that regulates the maturation and secretion of proinflammatory cytokines including interleukin(IL)-1β and IL-18 by activating the cysteine-containing aspartic acid protease and thus induces inflammatory response.Mtabolic stress including hyperglycemia,high blood free fatty acids,and hyperuricemia can activate NLRP3 inflammasome.Thus,NLRP3 inflammasome has became a new target in the treatment of diabetes and its chronic complications.This article reviews the relationship between NLRP3 inflammasome and chronic complications of diabetes and the therapeutic effects of Chinese herbal medicine.
作者 孙青 梁晓春
机构地区 中国医学科学院北京协和医学院北京协和医院中医科
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2018年第1期116-121,共6页 Acta Academiae Medicinae Sinicae
基金 国家自然科学基金(81603481) 北京协和医院中青年科研基金(pumch-2013-140)~~
关键词 NLRP3炎症小体 糖尿病慢性并发症 中药 NLRP3 inflammasome chronic complications of diabetes Chinese herbal medicine
分类号 R587.2 [医药卫生—内分泌]
  • 相关文献

参考文献1

二级参考文献18

  • 1Gluhovschi G, Gluhovschi C, Bob F, et al. Trandafirescu immune compartments of the nephron in relation to the immune system[ J]. Romanian J Inter Med, 2010,48( 1 ) :17-31.
  • 2Rodriguez IB, Johson R J, Hen'era AJ. Tubulointerstitial damage and progression of renal failure [ J ]. Kidn Intern Supp, 2005, (99) :82-86.
  • 3Martinon F, Bums K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and process- ing ofpro IL-113[ J]- nol Cell, 2002,10(2) :417-426.
  • 4Bauemfeind F, Ablasser A, Bartok E, et al. Inflammasomes : cur- rent understanding and open questions [ J ]. Cell Mol Life Sci, 2011,68 (5) :765-783.
  • 5Tran TH, Pham JT, Shafeeq H, et al. Role of interleukin-1 inhibi- torsin the management of gout [ J ]. Pharmacotherapy, 2013,33 ( 7 ) : 744 -753.
  • 6Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interaeting protein links oxidative stress to inflammasome activation [ J ]. Nat Immunol, 2010,11 (2) : 136-140.
  • 7Halle A, Homung V, Petzold GC, et al. The NALP3 inflamma- some is involved in the innate immune response to amyloid-β[ J ]. Nat Immunol, 2008,9(8) :857-865.
  • 8Li X, Zhang Y, Xia M, et al. Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and migration;implication of a novel role of inflammasome in atherogenesis [ J ]. PLoS One, 2014,9( 1 ) :87552.
  • 9Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-l-receptor antagonist in type 2 diabetes mellitus[ J]. N Engl J Med, 2007, 356(15) :1517-1526:.
  • 10Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases[J]. Nat Rev Rheumatol, 2010,6(4) :232-241.

共引文献13

同被引文献60

引证文献5

二级引证文献26

中国医学科学院学报
2018年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部